Serum miR-106b upregulation predicts poor prognosis in patients with colorectal cancer
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Serum miR-106b upregulation predicts poor prognosis in patients with colorectal cancer
Authors
Keywords
-
Journal
Cancer Biomarkers
Volume -, Issue -, Pages 1-7
Publisher
IOS Press
Online
2018-06-01
DOI
10.3233/cbm-181246
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MiR-106b and miR-93 regulate cell progression by suppression of PTEN via PI3K/Akt pathway in breast cancer
- (2017) Nana Li et al. Cell Death & Disease
- Effect of miR-106b on Invasiveness of Pituitary Adenoma via PTEN-PI3K/AKT
- (2017) Zhiming Zheng et al. MEDICAL SCIENCE MONITOR
- MicroRNA-106b is involved in transforming growth factor β1–induced cell migration by targeting disabled homolog 2 in cervical carcinoma
- (2016) Yuan Cheng et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- miR-106b promotes cancer progression in hepatitis B virus-associated hepatocellular carcinoma
- (2016) Chia-Sheng Yen WORLD JOURNAL OF GASTROENTEROLOGY
- MicroRNA-106b promotes colorectal cancer cell migration and invasion by directly targeting DLC1
- (2015) Guang-jun Zhang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- MiR-106b induces cell radioresistance via the PTEN/PI3K/AKT pathways and p21 in colorectal cancer
- (2015) Lin Zheng et al. Journal of Translational Medicine
- Inhibition of Ovarian Epithelial Carcinoma Tumorigenesis and Progression by microRNA 106b Mediated through the RhoC Pathway
- (2015) Shuo Chen et al. PLoS One
- Down-regulation of miRNA-106b inhibits growth of melanoma cells by promoting G1-phase cell cycle arrest and reactivation of p21/WAF1/Cip1 protein
- (2015) Ram Prasad et al. Oncotarget
- Recent advances in personalized colorectal cancer research
- (2014) Sarah Kraus et al. CANCER LETTERS
- Upregulation of microRNA-106b is associated with poor prognosis in hepatocellular carcinoma
- (2014) Bin-Kui Li et al. Diagnostic Pathology
- Serum miR-200c Is a Novel Prognostic and Metastasis-Predictive Biomarker in Patients With Colorectal Cancer
- (2013) Yuji Toiyama et al. ANNALS OF SURGERY
- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Downregulation of miR-106b induced breast cancer cell invasion and motility in association with overexpression of matrix metalloproteinase 2
- (2013) Xiaojian Ni et al. CANCER SCIENCE
- MicroRNA-106b regulates the tumor suppressor RUNX3 in laryngeal carcinoma cells
- (2013) Xu Ying et al. FEBS LETTERS
- Serum miR-21 as a Diagnostic and Prognostic Biomarker in Colorectal Cancer
- (2013) Yuji Toiyama et al. JNCI-Journal of the National Cancer Institute
- Over-Expression of miR-106b Promotes Cell Migration and Metastasis in Hepatocellular Carcinoma by Activating Epithelial-Mesenchymal Transition Process
- (2013) Wing Lung Yau et al. PLoS One
- MiR-106b promotes cell proliferation via targeting RB in laryngeal carcinoma
- (2011) Kemin Cai et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Non-coding RNAs in human disease
- (2011) Manel Esteller NATURE REVIEWS GENETICS
- MicroRNAs and Glial Cell Development
- (2011) Kang Zheng et al. NEUROSCIENTIST
- Therapeutic strategy in unresectable metastatic colorectal cancer
- (2011) Benoist Chibaudel et al. Therapeutic Advances in Medical Oncology
- Initial study of microRNA expression profiles of colonic cancer without lymph node metastasis
- (2010) Ying Xin WANG et al. Journal of Digestive Diseases
- CT Colonography Versus Optical Colonoscopy for Screening Asymptomatic Patients for Colorectal Cancer
- (2009) Robert H. El-Maraghi et al. ACADEMIC RADIOLOGY
- MicroRNAs: Target Recognition and Regulatory Functions
- (2009) David P. Bartel CELL
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started